{"nctId":"NCT03271021","briefTitle":"A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris","startDateStruct":{"date":"2017-07-17","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":1488,"armGroups":[{"label":"FMX101, 4% minocycline foam","type":"EXPERIMENTAL","interventionNames":["Drug: FMX101"]},{"label":"Vehicle foam","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Foam"]}],"interventions":[{"name":"FMX101","otherNames":[]},{"name":"Vehicle Foam","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Has facial acne vulgaris with:\n\n   1. 20 to 50 inflammatory lesions (papules, pustules, and nodules)\n   2. 25 to 100 non-inflammatory lesions (open and closed comedones)\n   3. No more than 2 nodules on the face\n   4. IGA score of moderate (3) to severe (4)\n2. Willing to use only the supplied non-medicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study.\n\nExclusion Criteria:\n\n1. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations.\n2. Sunburn on the face.","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12.","description":"A decrease in the inflammatory lesion count from Baseline to Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.39","spread":null},{"groupId":"OG001","value":"12.74","spread":null}]}]}]},{"type":"PRIMARY","title":"Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]}]},{"type":"SECONDARY","title":"The Absolute Change From Baseline in the Non-inflammatory Lesion Count at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.80","spread":null},{"groupId":"OG001","value":"15.89","spread":null}]}]}]},{"type":"SECONDARY","title":"The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 9","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.59","spread":null},{"groupId":"OG001","value":"11.72","spread":null}]}]}]},{"type":"SECONDARY","title":"The Absolute Change From Baseline in the Inflammatory Lesion Count at the Interim Visit at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.09","spread":null},{"groupId":"OG001","value":"9.57","spread":null}]}]}]},{"type":"SECONDARY","title":"IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":737},"commonTop":[]}}}